Recent Updates
Recently added Catalysts

HMPL-760 planned dose 1

Phase 2

Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Small molecule | Oncology |HUTCHMED (China) Limited|Last Updated: Jun 5, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment61
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06601504Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLPHASE2 ACTIVE NOT_RECRUITING 61 — — Nov 1, 2024Nov 1, 2026Jun 5, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
HMPL-760 planned dose 1DRUGHMPL-760 planned dose 1 daily (QD) orally
R-GemOxDRUGR-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
HMPL-760 placebo planned dose 1DRUGHMPL-760 placebo planned dose 1 daily (QD) orally
HMPL-760 planned dose 2DRUGHMPL-760 planned dose 2 daily (QD) orally
HMPL-760 placebo planned dose 2DRUGHMPL-760 placebo planned dose 2 daily (QD) orally
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06601504studyFirstPostDate: changed